Azvudine for the Treatment of COVID-19 in Pre-Existing Cardiovascular Diseases: A Single-Center, Real-World Experience.

Publication date: Mar 27, 2024

COVID-19 can lead to adverse outcomes in patients with pre-existing diseases. Azvudine has been approved for treating COVID-19 in China, but the real-world data is limited. It is aimed to investigate the efficacy of Azvudine in patients with COVID-19 and pre-existing cardiovascular diseases. Patients with confirmed COVID-19 and pre-existing cardiovascular diseases are retrospectively enrolled. The primary outcome is all-cause death during hospitalization. Overall, 351 patients are included, with a median age of 74 years, and 44% are female. 212 (60. 6%) patients are severe cases. Azvudine is used in 106 (30. 2%) patients and not in 245 (69. 8%). 72 patients died during hospitalization. After multivariate adjustment, patients who received Azvudine a lower risk of all-cause death (hazard ratio: 0. 431; 95% confidence interval: 0. 252-0. 738; p = 0. 002) than controls. Azvudine therapy is also associated with lower risks of shock and acute kidney injury. For sensitivity analysis in the propensity score-matched cohort (n = 90 for each group), there is also a significant difference in all-cause death between the two groups (hazard ratio: 0. 189; 95% confidence interval: 0. 071-0. 498; p

Concepts Keywords
China Azvudine
Drugs cardiovascular diseases
Hospitalization COVIDÔÇÉ19
Kidney death
Years outcome


Type Source Name
disease MESH COVID-19
disease MESH Cardiovascular Diseases
disease MESH death
disease MESH shock
disease MESH acute kidney injury

Original Article

(Visited 1 times, 1 visits today)